Dyne Therapeutics (DYN), a developer of therapies for muscle diseases plans an IPO of 10.3M shares, to be priced in a range of $16 to $18.
J.P. Morgan, Jefferies, Piper Sandler and Stifel are underwriting the deal.
Proceeds will be used to finance R&D, develop the FORCE platform and for general corporate purposes.
https://seekingalpha.com/news/3612839-dyne-therapeutics-sets-ipo-terms
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.